DARE Bioscience Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: Ended Q2 2026 with approximately $12.6 million in cash and cash equivalents.

Revenue: Total revenue for the quarter was $200,000, a significant increase from -$21,000 in Q2 2025, primarily from research and development services and royalties. Revenue from Flora Sync LF5 sales began in July, thus not included in Q2 results.

Expenses:

Selling, General and Administrative (SG&A) expenses increased to $2.6 million from $2.4 million in the prior year, mainly due to a non-cash write-down and investments in commercial readiness.

Research and Development (R&D) expenses decreased to $200,000 from $1.4 million, reflecting non-dilutive funding offsetting direct costs.

Net Loss: Improved to approximately $3 million, compared to $4 million in Q2 2025.

2Strategic Updates and Business Highlights

Commercialization Strategy: DARE launched its first product, Flora Sync LF5, in June 2026, marking its entry into direct commercialization. A second product, DARE-VVA1 Sildenafil Cream, is expected to begin prescription dispensing this quarter.

Product Details:

Flora Sync LF5: is a non-hormonal probiotic aimed at improving vaginal health, backed by clinical research.

DARE-VVA1: addresses female sexual arousal disorder, targeting a market of approximately 20 million women in the U.S., with a potential market size of $2 billion.

Dual Regulatory Pathway: The company is pursuing both a compounded product route and FDA approval for DARE-VVA1 to enhance market confidence and adoption.

Dare Health Hub: A central platform for education, product access, and telehealth services aimed at enhancing consumer engagement and brand loyalty.

3Forward Guidance and Outlook

Revenue Expectations: Anticipates revenue from DARE-VVA1 to begin in Q3 2026, with a diversified revenue profile expected across 2026 and 2027 as more products launch.

Growth Strategy: Focused on disciplined execution and establishing performance benchmarks to support growth in 2027 and beyond.

4Bad News, Challenges, or Points of Concern

Working Capital Deficit: The company reported a working capital deficit of approximately $200,000, which could pose challenges for operational flexibility.

Regulatory Risks: The FDA's recommendations for a minimum of 250 completers in clinical trials for Ovaprene could complicate timelines and regulatory approval processes.

Market Competition: The company faces competition in the women's health space, particularly in hormone replacement therapy, which could impact market penetration and adoption rates.

5Notable Q&A Insights

Brand Strategy: Sabrina Martucci Johnson emphasized the importance of the Dare brand in building credibility with both clinicians and consumers, aiming to leverage established healthcare relationships while also engaging directly with women through digital marketing and education.

DARE-HRT1 Potential: There is significant anticipation for DARE-HRT1, with clinicians expressing eagerness for its availability due to the lack of convenient hormone therapy options. The product is expected to meet clinical needs effectively, potentially converting users from compounded products to DARE's offerings. Overall, DARE Bioscience is positioned to capitalize on its recent product launches and strategic initiatives in the women's health sector, although it must navigate regulatory challenges and market competition as it seeks to establish a sustainable revenue stream.